Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Chief Medical Officer | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LB PHARMACEUTICALS INC
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Emplopyee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.22 · Expires 2036-10-08 | Direct | 200,000 |
Reported balance
After 2026-10-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 200,000 · Balance 200,000 F1: One fourth (1/4th) of the shares subject to the option award shall vest on September 14, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4th) of the shares subject to the option award shall vest on September 14, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 20:10 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmplopyee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $37.22 | $0.00 |
DisclosureSEC source: 0002150267-26-000005 · form4-10132026_041001.xml · derivative · entry 1 Kozauer Susan Gani · CIK 0002150267 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-10-08 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on September 14, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.